Ezrin-derived peptides and pharmaceutical compositions — US9682140B2
Patent disclosure · 2017
- What the patent describes
- Ezrin-related patent chemistry and experimental examples
- Reported evidence
- The granted claim class defines modified ezrin-derived peptides, including GEKKRRETVEREGG. A dependent composition also includes the parent Gepon sequence TEKKRRETVEREKE. Modified peptides and mixtures must not inherit Gepon clinical outcomes.
Phospho-ERK1 · 0.40 ± 0.02 after HP-V2 versus 0.10 ± 0.002 negative control · Normalized laboratory signal; positive TGF-β1 control 0.50 ± 0.02 · 1 hour · p<0.01
Reported patent results
Reported findings
The modified peptide increased MAPK/ERK phosphorylation in cell cultures.
Fibroblast signaling experiments with modified ezrin-derived HP-V2; a different sequence from parent Gepon.
Population or model Ezrin-related patent chemistry and experimental examples
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Phospho-ERK1 | 0.40 ± 0.02 after HP-V2 versus 0.10 ± 0.002 negative control | Normalized laboratory signal; positive TGF-β1 control 0.50 ± 0.02 · 1 hour · p<0.01 |
| Phospho-ERK2 | 1.30 ± 0.05 versus 0.40 ± 0.01 negative control | Positive TGF-β1 control 1.90 ± 0.10 · 1 hour · p<0.01 |
A fibroblast pathway response does not prove tissue repair or clinical efficacy. Values belong to HP-V2, not automatically Gepon, related fragments or every mixture.
Source for these results ↗ · Reviewed 2026-11-06
Patent claims and provenance
Molecule. Ezrin-derived peptide and composition claims; the claimed modified sequences are not automatically identical to the parent Gepon peptide or every marketed formulation.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- US9682140B2 ↗ · 2017-06-20
- Earliest priority / filing
- 2015-06-01 / 2016-06-01
- Original applicant / assignee
- Nearmedic International Ltd
- Indexed status
- Active · checked 2026-11-06
- Patent family
- 56117690 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Ezrin-derived peptides and pharmaceutical compositions thereof
Inventors: Rupert Holms; Ravshan Ataullakhanov; Rustam Ataullakhanov; Khachik Sayadyan.
US9682140B2 · EP3191504B1 · JP6721419B2 · KR101842978B1 · CN106188267B · AU2016203656B2 · CA2931875C · CY1120501T1 · DK3191504T3 · ES2660894T3 · GB2546439B · HRP20180560T1 · HUE038737T2 · LT3191504T · MA39421A · MD3191504T2 · ME03033B · MX377333B · PL3191504T3 · PT3191504T · RS57067B1 · SG10201604401UA · SI3191504T1 · SMT201800190T1 · WO2016193285A1 · ZA201603723B
Study limitations and source details
Study limitations
- Modified sequences and mixtures must not inherit Gepon outcomes.
- Clinical evidence appraisal remains pending.
Source details
Selected original-source text checked; full methodological review pending.
Selected text reviewed
Sources checked
Citation
Author unconfirmed. Ezrin-derived peptides and pharmaceutical compositions — US9682140B2 Primary source linked above